{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-24-000083","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.852513+00:00","generated_at":"2026-05-31T02:31:54.517657+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M","bullets":["$15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.","CT-202 (formerly BA3362) IND filing expected mid-2026; Context to fund all development.","Cash runway into 2027 covering CTIM-76 and CT-95 Phase 1 trials plus CT-202 IND expenses.","First CTIM-76 patient dosing expected Oct/Nov 2024; initial dose escalation data 1H 2026.","CT-95 Phase 1 initial dose escalation data expected mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-24-000083","json":"https://secwatch.observer/filing/0001842952-24-000083.json","markdown":"https://secwatch.observer/filing/0001842952-24-000083.md","text":"https://secwatch.observer/filing/0001842952-24-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000083/0001842952-24-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000083/cntx-20240923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:31:54.517657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}